Manner Carrie Eglinton Purchases 78,625 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton acquired 78,625 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $3.15 per share, with a total value of $247,668.75. Following the completion of the transaction, the chief executive officer now owns 1,259,664 shares of the company’s stock, valued at approximately $3,967,941.60. The trade was a 6.66 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

OraSure Technologies Stock Up 11.2 %

OSUR opened at $3.48 on Friday. OraSure Technologies, Inc. has a 12-month low of $2.68 and a 12-month high of $7.81. The stock has a market cap of $259.59 million, a price-to-earnings ratio of 23.20 and a beta of 0.05. The business has a 50 day moving average of $3.78 and a 200-day moving average of $4.00.

Wall Street Analyst Weigh In

Separately, StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, February 22nd.

Institutional Trading of OraSure Technologies

A number of hedge funds have recently made changes to their positions in OSUR. Price T Rowe Associates Inc. MD increased its stake in shares of OraSure Technologies by 5.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 76,932 shares of the medical instruments supplier’s stock worth $278,000 after purchasing an additional 3,828 shares during the period. Invesco Ltd. increased its stake in shares of OraSure Technologies by 3.4% during the fourth quarter. Invesco Ltd. now owns 127,526 shares of the medical instruments supplier’s stock worth $460,000 after purchasing an additional 4,240 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of OraSure Technologies by 202.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 5,234 shares during the period. Legal & General Group Plc increased its stake in shares of OraSure Technologies by 32.3% during the fourth quarter. Legal & General Group Plc now owns 23,626 shares of the medical instruments supplier’s stock worth $85,000 after purchasing an additional 5,770 shares during the period. Finally, Orion Portfolio Solutions LLC increased its stake in shares of OraSure Technologies by 10.7% during the fourth quarter. Orion Portfolio Solutions LLC now owns 61,170 shares of the medical instruments supplier’s stock worth $221,000 after purchasing an additional 5,929 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.